Published in Pigment Cell Melanoma Res on January 06, 2014
Genomic landscape of cutaneous T cell lymphoma. Nat Genet (2015) 1.27
Targeting RAS-mutant cancers: is ERK the key? Trends Cancer (2015) 0.82
Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res (2014) 0.82
Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib. Oncogene (2016) 0.80
The utility of transposon mutagenesis for cancer studies in the era of genome editing. Genome Biol (2015) 0.76
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A (1992) 35.45
Cancer genome landscapes. Science (2013) 25.33
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell (2005) 7.29
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64
A versatile tool for conditional gene expression and knockdown. Nat Methods (2006) 2.92
Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol (2001) 2.90
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res (2012) 1.39
Resistance to RAF inhibitors revisited. J Invest Dermatol (2013) 1.33
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma. Proc Natl Acad Sci U S A (2013) 1.04
piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS One (2011) 0.95
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Pigment Cell Melanoma Res (2013) 0.92
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
PeakSeq enables systematic scoring of ChIP-seq experiments relative to controls. Nat Biotechnol (2009) 11.28
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev (2003) 9.58
Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol (2002) 8.04
Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell (2005) 7.29
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
Overview of BioCreative II gene normalization. Genome Biol (2008) 5.05
AlleleSeq: analysis of allele-specific expression and binding in a network framework. Mol Syst Biol (2011) 4.71
GeneWays: a system for extracting, analyzing, visualizing, and integrating molecular pathway data. J Biomed Inform (2004) 4.57
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature (2012) 4.26
A genetic screen in Drosophila for metastatic behavior. Science (2003) 4.09
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell (2008) 3.29
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
SUN1/2 and Syne/Nesprin-1/2 complexes connect centrosome to the nucleus during neurogenesis and neuronal migration in mice. Neuron (2009) 3.10
SUN1 is required for telomere attachment to nuclear envelope and gametogenesis in mice. Dev Cell (2007) 3.09
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Quantifying environmental adaptation of metabolic pathways in metagenomics. Proc Natl Acad Sci U S A (2009) 2.89
Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion. Nature (2010) 2.79
Introducing meta-services for biomedical information extraction. Genome Biol (2008) 2.78
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
Primary care physician time utilization before and after implementation of an electronic health record: a time-motion study. J Biomed Inform (2004) 2.68
Yale Image Finder (YIF): a new search engine for retrieving biomedical images. Bioinformatics (2008) 2.67
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Loss of cell polarity drives tumor growth and invasion through JNK activation in Drosophila. Curr Biol (2006) 2.63
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Res (2008) 2.28
Syne-1 and Syne-2 play crucial roles in myonuclear anchorage and motor neuron innervation. Development (2007) 2.27
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov (2012) 2.27
Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res (2009) 2.13
SUN1 and SUN2 play critical but partially redundant roles in anchoring nuclei in skeletal muscle cells in mice. Proc Natl Acad Sci U S A (2009) 2.07
Elimination of oncogenic neighbors by JNK-mediated engulfment in Drosophila. Dev Cell (2011) 2.07
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
Towards semantic role labeling & IE in the medical literature. AMIA Annu Symp Proc (2005) 2.00
MicroRNA signatures differentiate melanoma subtypes. Cell Cycle (2011) 1.99
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97
Basement membrane remodeling is essential for Drosophila disc eversion and tumor invasion. Proc Natl Acad Sci U S A (2007) 1.97
Intrinsic tumor suppression and epithelial maintenance by endocytic activation of Eiger/TNF signaling in Drosophila. Dev Cell (2009) 1.95
Electronic health records in specialty care: a time-motion study. J Am Med Inform Assoc (2007) 1.88
Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell (2006) 1.88
LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1. Nat Cell Biol (2004) 1.86
An innate immune response of blood cells to tumors and tissue damage in Drosophila. Dis Model Mech (2008) 1.84
Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science (2009) 1.83
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry (2011) 1.76
Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol (2008) 1.73
Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia. Cell Metab (2013) 1.72
Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem (2005) 1.71
Tumor suppressor CYLD regulates JNK-induced cell death in Drosophila. Dev Cell (2007) 1.68
Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. Sci Signal (2010) 1.68
KASH protein Syne-2/Nesprin-2 and SUN proteins SUN1/2 mediate nuclear migration during mammalian retinal development. Hum Mol Genet (2010) 1.59
EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget (2010) 1.53
Role of trehalose phosphate synthase in anoxia tolerance and development in Drosophila melanogaster. J Biol Chem (2001) 1.46
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol (2009) 1.44
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol (2011) 1.42
Diagnostic accuracy of quantitative angiographic and intravascular ultrasound parameters predicting the functional significance of single de novo lesions. Int J Cardiol (2012) 1.42
A large-scale functional approach to uncover human genes and pathways in Drosophila. Cell Res (2008) 1.42
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res (2007) 1.41
Shaping cells and organs in Drosophila by opposing roles of fat body-secreted Collagen IV and perlecan. Dev Cell (2011) 1.41
Domain mapping of the polycystin-2 C-terminal tail using de novo molecular modeling and biophysical analysis. J Biol Chem (2008) 1.40
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene (2002) 1.38
ADAM10 is essential for proteolytic activation of Notch during thymocyte development. Int Immunol (2008) 1.38
A cell-intrinsic role for Mst1 in regulating thymocyte egress. J Immunol (2009) 1.35
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res (2003) 1.31
Crystal structure of CCM3, a cerebral cavernous malformation protein critical for vascular integrity. J Biol Chem (2010) 1.30
Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. Cell (2002) 1.29